EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Targeting CCR7 Attenuates Aggressive Phenotypes in Diffuse Large B‐Cell Lymphoma by Suppressing Wnt/β‐Catenin Signaling

Keke Huang iD, Jinlan Li, Ying Pan iD, Jiawen Chen, Shanyue Jiang, Yunjiao Yao, Zelin Liu, Dandan Chen, Yajie Zhang, Huiping Wang iD, Yang Wan, Qing Zhang iD und 4 weitere

Cancer Medicine · 2026-11 · 15 (11)

DOI: 10.1002/cam4.72437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 11.11.2026. Verfasst von Keke Huang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Receptors, CCR7, Lymphoma, Large B-Cell, Diffuse, Wnt Signaling Pathway. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Anhui Province Clinical Medical Research Translation Program, Scientific Research Foundation of Education Department of Anhui Province of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The CCL21/CCR7 chemokine axis is implicated in lymphocyte trafficking and cancer metastasis, yet its specific role and molecular mechanism in the pathogenesis of diffuse large B‐cell lymphoma (DLBCL) remain poorly defined.

Methods

CCR7 expression was assessed in clinical samples by immunohistochemistry and flow cytometry. In vitro functional assays and molecular techniques were employed in DLBCL cell lines to investigate the CCL21/CCR7 axis. Downstream mechanisms were investigated through RNA sequencing, Co‐immunoprecipitation (Co‐IP), and rescue experiments using the Wnt/β‐catenin inhibitor XAV‐939.

Results

CCR7 was significantly overexpressed in aggressive DLBCL and correlated with advanced disease stage and poor prognosis. The CCL21/CCR7 axis significantly promoted tumor cell migration, invasion, resistance to apoptosis, and mesenchymal‐like phenotypic changes. Transcriptomic profiling revealed the Wnt/β‐catenin pathway as the most significantly enriched downstream target. Mechanistically, CCL21/CCR7 activation was associated with enhanced Wnt/β‐catenin signaling and a potential physical association between CCR7 and β‐catenin‐containing protein complexes. Inhibition of Wnt/β‐catenin signaling attenuated CCL21‐induced malignant phenotypes. As a potential therapeutic intervention, the anti‐CCR7 monoclonal antibody CAP‐100 attenuated CCR7‐associated signaling, inhibited Wnt/β‐catenin activation, reversed mesenchymal‐like phenotypic changes, and suppressed the malignant behaviors of DLBCL cells in vitro.

Conclusion

Our study provides novel insights into DLBCL pathogenesis by suggesting that the CCL21/CCR7 axis contributes to tumor aggressiveness at least partly through activation of the Wnt/β‐catenin pathway, leading to mesenchymal‐like phenotypic remodeling. These findings support CCR7 as a potential therapeutic target and suggest that antibody‐mediated CCR7 blockade warrants further in vivo validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CCR7Lymphoma, Large B-Cell, DiffuseWnt Signaling PathwayHumansCell Line, TumorPhenotypeChemokine CCL21FemaleGene Expression Regulation, NeoplasticAnimalsCell MovementMalebeta CateninCell ProliferationApoptosisHeterocyclic Compounds, 3-Ring

Stichwörter der Autor:innen

Wnt signaling pathwaychemokine ligand 21chemokine receptor 7diffuse large B‐cell lymphomamesenchymal‐like phenotypic remodeling

Substanzen

Receptors, CCR7CCR7 protein, humanChemokine CCL21CCL21 protein, humanXAV939beta CateninHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • The Second School of Clinical Medicine Center for Emerging Medical Sciences, Anhui Medical University, Hefei, Anhui, China.
  • Department of Nephropathy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

ORCID-Profile: Keke Huang, Ying Pan, Huiping Wang, Qing Zhang, Jiyu Wang

Förderung

  • National Natural Science Foundation of China
  • Anhui Province Clinical Medical Research Translation Program
  • Scientific Research Foundation of Education Department of Anhui Province of China
  • Health Research Program of Anhui

Zitieren

APA

Huang, K., Li, J., Pan, Y., Chen, J., Jiang, S., Yao, Y., Liu, Z., Chen, D., Zhang, Y., Wang, H., Wan, Y., Zhang, Q., An, F., Tao, Q., Zhai, Z., & Wang, J. (2026). Targeting CCR7 Attenuates Aggressive Phenotypes in Diffuse Large B‐Cell Lymphoma by Suppressing Wnt/β‐Catenin Signaling. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72437

Vancouver

Huang K, Li J, Pan Y, Chen J, Jiang S, Yao Y, et al. Targeting CCR7 Attenuates Aggressive Phenotypes in Diffuse Large B‐Cell Lymphoma by Suppressing Wnt/β‐Catenin Signaling. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72437

BibTeX
@article{Huang2026,
  author = {Huang, Keke and Li, Jinlan and Pan, Ying and Chen, Jiawen and Jiang, Shanyue and Yao, Yunjiao and Liu, Zelin and Chen, Dandan and Zhang, Yajie and Wang, Huiping and Wan, Yang and Zhang, Qing and An, Furun and Tao, Qianshan and Zhai, Zhimin and Wang, Jiyu},
  title = {Targeting CCR7 Attenuates Aggressive Phenotypes in Diffuse Large B‐Cell Lymphoma by Suppressing Wnt/β‐Catenin Signaling},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/cam4.72437}
}
Kostenlos starten →